Treatment of Dry Eye Disease Using Mitochondrially Targeted Antioxidants
AssigneeMitotech SA
InventorsMaxim SKULACHEV, Anton PETROV
Life of this patent
Estimating the term…
Abstract
Formulations and methods of using mitochondrially targeted antioxidants (SkQ) to improve dry eye conditions in subjects having a tear production of ≥7 mm measured by a Schirmer's test are provided. The methods provide benefits to the population-specific group of subjects but do not provide benefits to subjects having a tear production of <7 mm, as measured by a Schirmer's test.
Claims33
A formulation comprising a compound of Formula I:
- wherein A is a quinone antioxidant having the following structure:
- and/or a reduced quinole form thereof;
- wherein m is an integer from 1 to 3, and each Y is independently selected from the group consisting of C1-6 alkyl and C1-6 alkoxy (—O—C1-6);
- wherein L is a linker group, comprising:
- a) a straight or branched hydrocarbon chain which can optionally be substituted by one or more substituents and which can optionally contain one or more double and/or triple bonds;
- and/or
- b) a natural isoprene chain;
- n is an integer from 1 to 40;
- B is a targeting group comprising Sk+Z−;
- wherein Sk+ is a lipophilic cation, and Z− is a pharmaceutically acceptable anion;
- wherein the formulation comprises SkQ at a concentration of ≥0.5 μg/mL;
- and
- wherein the formulation is suitable to aid in treating a subject having a dry eye condition. the subject's eye having a tear production of ≥7 mm measured by a Schirmer's test, and providing an improvement in one or more signs and/or one or more symptoms of dry eye disease.
The formulation of any of the preceding claims, wherein the formulation is an eye-drop or eye-gel formulation and is suitable to be applied topically to the eye and/or to one or more adnexa of the eye.
The formulation of any of the preceding claims, wherein the one or more signs of dry eye disease comprise a grade of corneal staining of >0 in the whole cornea or a portion thereof.
The formulation of any of the preceding claims, wherein the one or more symptoms of dry eye disease comprise an index of blurred vision ≥1 or poor vision ≥1, and/or a reduced visual acuity of the eye.
The formulation of any of the preceding claims, wherein the formulation is suitable to be applied topically to the eye, and the formulation is suitable to contact one or more adnexa of the eye via a spreading of the formulation on the surface of the eye, an eye blink, an eye movement, or a combination thereof.
The formulation of any of the preceding claims, wherein the one or more or said signs of dry eye disease comprise a grade of corneal staining >0 in the whole cornea or a portion thereof, and the one or more symptoms of dry eye disease comprise a reduced visual acuity of the eye.
The formulation of any of the preceding claims, wherein the formulation is suitable for use in a method comprising the steps of:
- (a) applying a fluorescein stain to the eye;
- (b) measuring a grade of central corneal fluorescein staining;
- (c) repeatedly treating the eye with the formulation after steps (a) and (b);
- thereby providing a reduction or a complete clearing in the grade of central corneal fluorescein staining of the eye.
The formulation of any of the preceding claims, wherein the subject has a reported index of blurred vision of ≥1 or poor vision of ≥1, and/or a reduced visual acuity of the eye before a treatment with the formulation, and wherein the formulation is suitable to provide an improvement in the visual acuity of the eye after the treatment.
The formulation of any of the preceding claims, wherein the one or more signs and/or the one or more symptoms of dry eye disease comprise one or more of the following:
- tear production in the eye of ≥7 mm by a Schirmer's test, a grade of central corneal fluorescein staining of >0, a total fluorescein corneal staining score of ≥2, a total lissamine green conjunctival staining score of ≥2, corneal sensitivity, conjunctival redness, lid margin redness, damage to the cornea, subject eye grittiness, eye itching or discomfort, reduced visual acuity, and subject reported blurred vision, poor vision, eye pain, eye photosensitivity, or eye pain.
The formulation of any of the preceding claims, wherein the formulation is suitable for treating the subject's eye over a period of about 14 days to about 90 days.
The formulation of any of the preceding claims, wherein the one or more signs and/or one or more symptoms of dry eye disease are associated with a condition comprising one or more of the following:
- eye strain due to reading, driving at night, watching a display screen, or contact lens wear, exposure to an environmental eye irritant, hormone replacement therapy, exposure to the wind or dry air, allergies, eye surgery, a side effect of a medication, thyroid disease, disease of aging, an infection, exposure keratitis, vitamin deficiency, Sjogren's syndrome, and a condition associated with keratoconjunctivitis sicca, keratitis sicca, or an immune system disorder.
The formulation of any of the preceding claims, wherein the SkQ comprises one or more compounds, in oxidized or reduced form, or a mixture thereof, selected from the group consisting of the following compounds:
The formulation of any of the preceding claims, wherein the pharmaceutically acceptable anion Z− comprises acetate, bromide, camsylate, chloride, formate, fumarate, maleate, mesylate, nitrate, oxalate, phosphate, dihydrogen phosphate dodecahydrate, dihydrogen phosphate dihydrate, sulfate, tartrate, thiocyanate, tosylate, adipate, caprate, caproate, caprylate, dodecylsulfate, glutarate, laurate, oleate, palmitate, sebacate, stearate, undecylenate, or a combination thereof.
The formulation of any of the preceding claims, wherein the SkQ optionally comprises a hydrate comprising one or more water molecules associated via a hydrogen bonding and/or an ionic bonding to the A, L, Sk+, and/or to Z−.
The formulation of any of the preceding claims, wherein the formulation is suitable for treating a subject at a dose of at least one drop or at least about 0.05 mL of the formulation to the eye and/or to one or more adnexa of the eye at least once every 24 hours.
The formulation of any of the preceding claims, wherein the formulation comprises one or more of the following:
- benzalkonium chloride, hypromellose, sodium chloride, sodium dihydrogen phosphate dihydrate, sodium dihydrogen phosphate dodecahydrate, and water.
The formulation of any of the preceding claims, wherein the Schirmer's test score is an unanesthetized Schirmer's test score.
The formulation of any of the preceding claims, wherein the one or more symptoms of dry eye disease comprise one or more symptoms reportable by the subject.
The formulation of any of the preceding claims, wherein the one or more signs and/or the one or more symptoms of dry eye disease arise from a progressive dry eye disease for longer than about 2 months.
The formulation of any of the preceding claims, wherein the formulation comprises SkQ at a concentration of ≥1 μg/mL.
A kit for treating one or more signs and/or one or more symptoms of dry eye disease, the kit comprising:
- a dispensing container comprising an eye-drop or eye-gel formulation comprising SkQ at a concentration of ≥0.5 μg/mL;
- and
- instructions for use.
Dependencies are inferred from the claim text.